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ABSTRACT
Objective To investigate the long- term risk of 
developing hypertension and cardiovascular disease 
(CVD) among those women who suffered a postpartum 
haemorrhage (PPH) compared with those women who 
did not.
Design Population- based longitudinal open cohort 
study.
Setting English primary care (The Health Improvement 
Network (THIN)) and secondary care (Hospital Episode 
Statistics (HES)) databases.
Population Women exposed to PPH during the study 
period matched for age and date of delivery, and 
unexposed.
Methods We conducted an open cohort study using 
linked primary care THIN and HES Databases, from 1 
January 1997 to 31 January 2018. A total of 42 327 
women were included: 14 109 of them exposed to PPH 
during the study period and 28 218 matched for age 
and date of delivery, and unexposed to PPH. HRs for 
cardiovascular outcomes among women who had and 
did not have PPH were estimated after controlling for 
covariates using multivariate Cox regression models.
Outcome measures Risk of hypertensive disease, 
ischaemic heart disease, heart failure, stroke or 
transient ischaemic attack.
Results During a median follow- up of over 4 years, 
there was no significant difference in the risk of 
hypertensive disease after adjustment for covariates 
(adjusted HR (aHR): 1.03 (95% CI: 0.87 to 1.22); 
p=0.71). We also did not observe a statistically 
significant difference in the risk of composite CVD 
(ischaemic heart disease, heart failure, stroke or 
transient ischaemic attack) between the exposed and 
the unexposed cohort (aHR: 0.86 (95% CI: 0.52 to 1.43; 
p=0.57).
Conclusion Over a median follow- up of 4 years, 
we did not observe an association between PPH and 
hypertension or CVD.
INTRODUCTION
The widely used definition of postpartum 
haemorrhage (PPH) is blood loss in excess of 
500 mL following birth.1 In 2017–2018, there 
were 626 203 deliveries in National Health 
Service (NHS) hospitals in England, of which 
19% were complicated by PPH.2 Over 100 000 
women a year in England suffer a PPH but 
the long- term health consequences beyond a 
year of experiencing PPH, aside from future 
fertility and mental health illness, have not 
been studied to date in the UK.3 4 The majority 
of the recognised risk factors for PPH are 
pregnancy related, such as placental abrup-
tion and hypertensive disorders of pregnancy 
which are also overarching risk factors for 
later development of cardiovascular disease 
(CVD).5 6
Disease unmasked in or around pregnancy 
such as pregnancy- induced hypertension, 
gestational diabetes mellitus (GDM), preterm 
labour and diseases of placentation including 
Strengths and limitations of this study
 ► A strength of this study was the adequate sample 
size and population- wide coverage.
 ► A strength of this study was the use of a matched 
controlled study design.
 ► The study benefited from adjustment for a wide 
range of relevant covariates.
 ► An acknowledged limitation of this study is the me-
dian follow- up of 4 years.
 ► A limitation of this study is identification of postpar-
tum haemorrhage and cardiovascular disease within 
the database and the potential to miss cases that 
were not correctly coded.
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fetal growth restriction and placental abruption have 
previously been demonstrated to identify women at 
high risk of long- term cardiovascular risk, as shown in 
a number of cohorts of women with adverse pregnancy 
outcomes.7–17
Given that hypertensive disorders of pregnancy increase 
the likelihood of PPH, it is possible that PPH is also a risk 
factor for later development of hypertension post partum. 
Hypertensive disease in pregnancy causes poor placenta-
tion; this combined with the higher mean arterial blood 
pressure could predispose to brisker blood loss after 
delivery.18 The PPH episode might therefore unmask the 
potential for endothelial or vascular dysfunction that may 
not have manifested as hypertensive disease in pregnancy, 
therefore remaining as a latent threat for hypertension 
and CVD in later life.19 The interplay between vascular 
smooth muscle and vascular endothelium is complex and 
dysfunction of their relationship is thought to be impli-
cated in first steps of pathogenesis contributing to CVD, 
peripheral vascular disease, stroke and chronic kidney 
disease.19
The risk of poor cardiovascular health in women who 
have undergone PPH is thus a possibility and warrants 
investigation.
To address the gap in our knowledge of the risks 
following a PPH, we did a cohort study examining the 
long- term risk of developing hypertension and CVD 
among those women who suffered a PPH compared with 
those women who did not.
METHODS
Study design and data sources
This study is a population- based retrospective open 
cohort study using linked primary care (The Health 
Improvement Network (THIN)) and secondary care 
(Hospital Episode Statistics (HES)) databases. THIN is a 
large population- based database in the UK that contains 
electronic medical records of over 17 million patients 
from 787 general practices (163 of them linked to the 
HES Database). The linkage of databases was performed 
in order to capture information on exposure (PPH) 
from HES, the long- term cardiovascular outcomes from 
THIN and important covariates from both THIN (demo-
graphics) and HES (records during hospital admission). 
THIN and HES Databases, on their own and linked, 
have been extensively used for epidemiological studies, 
including longitudinal studies that examine long- term 
outcomes in women with exposure during pregnancy.20–22 
Core outcomes sets exist for studies evaluating interven-
tions for prevention and treatment of PPH rather than 
epidemiological outcomes following PPH and were there-
fore not used.
Patient and public involvement
We did not seek patient and public involvement for this 
study in line with current practice for epidemiology 
research.
Study population
Women aged between 16 and 46 years who had a record 
of delivery in HES (which contains information on admis-
sions to NHS hospitals in England) between 1 January 
1990 and 31 January 2018 (index delivery) were eligible 
to be included. Patients in THIN were considered for data 
linkage 12 months after registration with their practice 
and where the practice had been using electronic medical 
records for a minimum of 12 months and had shown 
acceptable mortality recording in the previous 12 months 
or before.20 These three criteria ensured data quality and 
sufficient time for maximum and accurate documenta-
tion of all covariates. The THIN–HES data linkage was 
performed by NHS Digital using patient- sensitive de- ano-
nymised data which were then anonymised and received 
by our team. Once linked, women with a HES record of 
PPH associated with the index delivery were identified 
to form the exposed cohort. For each woman exposed 
to PPH, we randomly selected two controls matched for 
date of birth (±1 year) and delivery date (±1 year). Cohort 
selection for this study is described in figure 1.
Follow-up period
Index date was the date of delivery for all women. Patients 
were followed up using THIN records until the earliest 
of the following: date they left the general practice, date 
they died, date the general practice ceased to contribute 
to the THIN Database, date the outcome of interest was 
recorded and study end date (31 December 2018).
Exposure definition
Exposure PPH was defined using International Classifica-
tion of Diseases, 10th Revision (ICD-10) codes recorded 
in HES. ICD-10 codes used to identify PPH have previ-
ously been used in national audits and other epidemio-
logical studies.23 24
Outcomes
Outcome ascertainment was performed using THIN 
Read Code records, a hierarchical coding system to docu-
ment symptoms, signs and diagnosis in primary care.25 
Hypertension following PPH was the primary outcome of 
interest. Composite CVD (ischaemic heart disease, stroke 
or transient ischaemic attack (TIA) and heart failure) 
and individual components of composite CVD following 
PPH were secondary outcomes. All outcomes have previ-
ously been studied extensively using THIN and are part of 
the Quality Outcome Framework in the UK, that requires 
mandatory maintenance of disease registers for these 
conditions and are thus expected to be documented 
rigorously.7 26 27
Covariates
Covariates that are independent predictors of outcome 
other than the exposure of interest were selected on the 
basis of biological plausibility and previous literature. 
Information on the following covariates was extracted 
from THIN: age, body mass index (BMI), socioeconomic 
status, smoking status, diagnoses of hypertensive disorders 
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(pre- existing or pregnancy- induced hypertension and 
pre- eclampsia), gestational diabetes and pre- existing 
diabetes and prescription records of lipid- lowering drugs.
Age was categorised as 15–19, >20–29, >30–39 and >40 
years. BMI was categorised according to the WHO’s clas-
sification as <18 kg/m2, 18–24 kg/m2, >25–29 kg/m2 and 
>30 kg/m2. Socioeconomic status in THIN is recorded as 
Townsend deprivation quintile graded from 1 to 5 with 
increasing degree of deprivation.
Information on the mode of delivery (spontaneous, 
caesarean and other delivery methods) was obtained from 
National Clinical Coding Standards (OPCS) recorded in 
HES.
Ethnicity data were derived from THIN and, when 
missing, HES records were used. Missing records of BMI, 
Townsend score and ethnicity were allocated into the 
‘missing category’ of the corresponding covariate.
Data analysis
Baseline data stratified by exposure are reported as 
mean (SD) or median (IQR) for continuous variables 
depending on the normality of the distribution and as 
frequency and proportions for categorical variables. Cox 
regression model was used to obtain crude and adjusted 
HRs (aHRs) taking into account the covariates described 
earlier. All analyses were performed in Stata V.14.0. 
For each outcome analysis, women with a Read Code 
recording (in THIN) of the outcome of interest prior to 
the indexed delivery were excluded.
RESULTS
A total of 42 327 women were included in our study: 14 
109 women exposed to PPH during index delivery and 
28 218 women unexposed to PPH. Baseline summary 
statistics stratified by the exposure status are provided 
in table 1. Mean ages at delivery were 30.90 (SD 5.72) 
and 30.85 (SD 5.68) years for women exposed and 
unexposed to PPH, respectively. Follow- up period was 
similar between women exposed and unexposed to PPH 
(median (IQR) follow- up in years: 4.13 (1.72–7.58) and 
4.15 (1.78–7.63), respectively). BMI recorded at base-
line was higher among the women exposed to PPH 
compared with women without PPH (median (IQR): 24.1 
(21.5–28.0) and 23.7 (21.2–27.4), respectively). There 
was no significant difference in socioeconomic status and 
ethnicity of women with and without PPH. Women who 
Figure 1 Cohort selection for the study. CVD, cardiovascular disease; HES, Hospital Episode Statistics; PPH, postpartum 
haemorrhage; THIN, The Health Improvement Network.
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experienced PPH were less likely to be smokers compared 
with women who did not experience PPH during delivery 
(2409 (17.07%) vs 5906 (20.93%)). Proportion of women 
with a record of pre- existing hypertension and diabetes 
and proportion prescribed with lipid- lowering drugs were 
similar between the two groups. However, there was a 
slightly higher proportion of women with GDM among 
the exposed compared with the unexposed (352 (2.49%) 
vs 597 (2.12%), respectively). There were also differences 
in the delivery methods between the two groups; higher 
proportion of women with PPH underwent caesarean 
section (5173 (36.66%) vs 7020 (24.88%)) and other 
non- spontaneous delivery methods (5576 (39.52%) vs 16 
422 (58.20%)).
Risk of hypertension
A total of 218 (1.6%) women exposed to PPH and 383 
(1.4%) women unexposed to PPH developed hyperten-
sion during follow- up, with an incidence rate of 3.12 
and 2.72 per 1000 person- years. There was no significant 
difference in the risk of hypertension between women 
who were exposed and unexposed to PPH (HR: 1.14 
(95% CI: 0.97 to 1.35, p=0.118), including after adjust-
ment for covariates (aHR: 1.03 (95% CI: 0.87 to 1.22); 
p=0.710) (see table 2).
Risk of CVD
Twenty- three (0.16%) women exposed to PPH and 52 
(0.18%) women unexposed to PPH developed at least 
Table 1 Baseline characteristics






Age (mean (SD)) 30.90 (5.72) 30.85 (5.68)
BMI (kg/m2) (median 
(IQR))
24.1 (21.5–28.0) 23.7 (21.2–27.4)
BMI categories (n 
(%))
  <18 kg/m2 239 (1.69) 635 (2.25)
  18–24 kg/m2 
(reference)
6742 (47.79) 14 015 (49.67)
  25–29 kg/m2 3100 (21.97) 5711 (20.24)
  ≥30 kg/m2 2164 (15.34) 3717 (13.17)
  Missing 1864 (13.21) 4140 (14.67)
Townsend deprivation 
quintile (n (%))
  1 (reference) 3341 (23.68) 6316 (22.38)
  2 2573 (18.24) 5035 (17.84)
  3 3087 (21.88) 6216 (22.03)
  4 2741 (19.43) 5582 (19.78)
  5 1567 (11.11) 3349 (11.87)
  Missing 800 (5.67) 1720 (6.10)
Smoking status (n 
(%))
  Non- smoker 
(reference)
8473 (60.05) 16 060 (56.91)
  Ex- smoker 2887 (20.46) 5552 (19.68)
  Smoker 2409 (17.07) 5906 (20.93)
  Missing 340 (2.41) 700 (2.48)
Baseline 
comorbidities (n (%))




and pre- existing 
hypertension)
298 (2.11) 518 (1.84)







128 (0.91) 227 (0.80)
  Pre- existing 
hypertension
186 (1.32) 306 (1.08)
  Gestational 
diabetes
352 (2.49) 598 (2.12)
  Pre- existing 
diabetes
120 (0.85) 200 (0.71)
  Combined 
cardiovascular 
disease
22 (0.16) 44 (0.16)
  Ischaemic heart 
disease
3 (0.02) 7 (0.02)
  Heart failure 0 (0.00) 2 (0.01)
Continued






  Stroke/TIA 19 (0.13) 39 (0.14)
Baseline drug 
prescription (n (%))
  Lipid- lowering 
drugs
51 (0.36) 115 (0.41)
Mode of delivery (n 
(%))
  Spontaneous 
(reference)
5576 (39.52) 16 422 (58.20)
  Caesarean 5173 (36.66) 7020 (24.88)
  Other delivery 
methods
3360 (23.81) 4776 (16.93)
Ethnicity (n (%))
  Caucasians 
(reference)
10 949 (77.60) 22 023 (78.05)
  South Asians 695 (4.93) 1340 (4.75)
  Afro- Caribbeans 502 (3.56) 894 (3.17)
  Mixed race 193 (1.37) 373 (1.32)
  Other race 490 (3.47) 953 (3.38)
  Missing 1280 (9.07) 2635 (9.34)
BMI, body mass index; PPH, postpartum haemorrhage; TIA, transient 
ischaemic attack.
Table 1 Continued









pen: first published as 10.1136/bm





5Parry- Smith W, et al. BMJ Open 2021;11:e041566. doi:10.1136/bmjopen-2020-041566
Open access
one of the three components of the composite cardio-
vascular outcome during follow- up. After adjustment for 
covariates, there was no significant difference in the risk 
of composite CVD between the exposed and the unex-
posed cohort (aHR: 0.86 (95% CI: 0.52 to 1.43; p=0.572) 
(see table 2). When the individual components of the 
CVD were analysed as outcomes, none of these indi-
vidual outcomes were significantly different between the 
exposed and the unexposed cohort (aHR—ischaemic 
heart disease: 1.00 (95% CI: 0.30 to 3.32); p=0.995, heart 
failure: 0.76 (95% CI: 0.25 to 2.31); p=0.634, and stroke or 
TIA: 0.79 (95% CI: 0.43 to 1.47); p=0.461) (see figure 2).
DISCUSSION
To our knowledge, this is the first English population- wide 
longitudinal study to date investigating cardiovascular risk 
following PPH and includes over 14 000 episodes of PPH 
and over 210 000 person- years of follow- up. Women who 
experienced PPH were found not to be at increased risk 
of developing hypertension nor composite CVD (heart 
failure, stroke or TIA and ischaemic heart disease) when 
compared with women who did not experience PPH.
The hypothesis that having PPH might unmask a latent 
risk of developing future CVD is, as discussed in the intro-
duction, plausible though not supported in the follow- up 
period of this study. PPH is thought to occur more 
frequently in those women with pre- existing congen-
ital heart disease.28 In episodes of severe PPH requiring 
admission to intensive care, myocardial ischaemia- 
induced injury was associated with severe PPH, though 
there was no long- term follow- up of these women.29 It has 
been speculated that the marked physiological response 
caused by a PPH might cause vulnerable arteriosclerotic 
plaque changes and precipitate coronary disease and 
myocardial infarction in the short term.30
CVD is a leading cause of death among women, and 
when combined with the high prevalence of PPH 
following childbirth, an association could have been 
of importance at individual and population levels. Our 
study provides reassurance for women who have had 
a PPH with regard to future cardiovascular risk up to 4 
years following delivery.31
Strengths and weaknesses
This study has several strengths including its sample 
size, population- wide coverage, and controlling for 
confounding by using the matched controlled study 
design and adjusting for a wide range of relevant covari-
ates. The finding that smoking is protective for PPH is 
in keeping with previous research and may be due to 
increased risk of poor uteroplacental blood flow in the 
smoking population and/or the hypercoagulation effects 
of smoking.32 33
Table 2 Crude and adjusted HR rate for hypertension and cardiovascular disease (CVD) among women who were exposed to 
PPH compared with women unexposed to PPH
Exposed to PPH Unexposed to PPH
Hypertension Total n 13 923 27 912
Outcomes, n (%) 218 (1.57) 383 (1.37)
Follow- up (person- years) 69 944 140 703
HR rate (95% CI); p value 1.14 (0.97 to 1.35); 0.118
Adjusted HR rate (95% CI); p value* 1.03 (0.87 to 1.22); 0.710
Composite CVD (ischaemic 
heart disease, heart failure, 
stroke/transient ischaemic 
attack)
Total n 14 087 28 174
Outcomes, n (%) 23 (0.16) 52 (0.18)
Follow- up (person- years) 71 666 143 724
HR rate (95% CI); p value 0.88 (0.54 to 1.44); 0.621
Adjusted HR rate (95% CI); p value† 0.86 (0.52 to 1.43); 0.572
*Adjusted for age category, BMI category, smoking status, ethnicity, Townsend deprivation quintile, baseline record of hypertensive disorders 
of pregnancy (pregnancy- induced hypertension and pre- eclampsia), gestational diabetes, pre- existing diabetes, baseline prescription of lipid- 
lowering drugs and delivery method.
†Adjusted for age category, BMI category, smoking status, ethnicity, Townsend deprivation quintile, baseline record of hypertensive disorders 
(pre- existing/pregnancy- induced hypertension and pre- eclampsia), gestational diabetes, pre- existing diabetes, baseline prescription of lipid- 
lowering drugs and delivery method.
BMI, body mass index; PPH, postpartum haemorrhage.
Figure 2 Adjusted HRs (aHRs) for different cardiovascular 
outcomes following exposure to postpartum haemorrhage.
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Measurement of blood loss and definition of PPH, 
however, are a challenge with recognised underestima-
tion of blood loss. We were only able to identify women 
who had PPH and CVD if it was coded in the database.
A previous study identified increased cardiovascular 
risk following maternal placental syndromes at between 
3 and 5 years following delivery.31 The follow- up period 
in our study was similar between women exposed and 
unexposed to PPH but the follow- up time frame could 
have been too short to observe an effect as relatively few 
women had a diagnosis of CVD. However, it is reassuring 
that the risk of cardiovascular events is highest immedi-
ately following delivery and decline over time.34
A recent well- conducted Canadian study reported that 
PPH was not associated with an increase in cardiovascular 
risk aHR of 1.02 (95% CI: 0.97 to 1.07), in line with the 
results of our study.34 A recent Korean study also supports 
the findings of our study in that there was no difference 
in the risk of CVD in women with PPH or without PPH 
after adjustment (HR: 0.96, 95% CI: 0.86 to 1.07), which 
is broadly comparable with our study (aHR: 0.86 (95% CI: 
0.52 to 1.43; p=0.57).35 However, when Cho et al35 exam-
ined only those women who had a PPH requiring a blood 
transfusion, the risk of CVD was significantly increased 
after adjustment (HR: 1.60, 95% CI: 1.25 to 2.06). We 
were unable to stratify our results by blood transfusion, 
which would have proven a useful approach.
Implications for clinical practice
Long- term morbidity and disease as a consequence of 
PPH deserves vigilance but there is no particular cause 
for concern regarding an increase in cardiovascular risk 
in this patient group. The long- term effects of PPH are 
little studied, the use of public/national data sets should 
increase the literature to address important public health 
questions.
CONCLUSION
Over a median follow- up of 4 years, we did not observe an 
association between PPH and hypertension or CVD.
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